ZA200709751B - Thiazole compounds and methods of use - Google Patents
Thiazole compounds and methods of useInfo
- Publication number
- ZA200709751B ZA200709751B ZA200709751A ZA200709751A ZA200709751B ZA 200709751 B ZA200709751 B ZA 200709751B ZA 200709751 A ZA200709751 A ZA 200709751A ZA 200709751 A ZA200709751 A ZA 200709751A ZA 200709751 B ZA200709751 B ZA 200709751B
- Authority
- ZA
- South Africa
- Prior art keywords
- methods
- thiazole compounds
- thiazole
- compounds
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US67913305P | 2005-05-09 | 2005-05-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200709751B true ZA200709751B (en) | 2008-11-26 |
Family
ID=36968742
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200709751A ZA200709751B (en) | 2005-05-09 | 2007-11-13 | Thiazole compounds and methods of use |
Country Status (18)
Country | Link |
---|---|
US (2) | US8088806B2 (ja) |
EP (1) | EP1879575A2 (ja) |
JP (1) | JP2008540537A (ja) |
KR (1) | KR20080019213A (ja) |
CN (1) | CN101247807A (ja) |
AP (1) | AP2358A (ja) |
AU (1) | AU2006244203B2 (ja) |
BR (1) | BRPI0608910A2 (ja) |
CA (1) | CA2607617A1 (ja) |
EA (1) | EA200702445A1 (ja) |
IL (1) | IL186970A0 (ja) |
MX (1) | MX2007013955A (ja) |
NO (1) | NO20075723L (ja) |
NZ (1) | NZ563866A (ja) |
SG (1) | SG159561A1 (ja) |
UA (1) | UA92746C2 (ja) |
WO (1) | WO2006122011A2 (ja) |
ZA (1) | ZA200709751B (ja) |
Families Citing this family (107)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2617532A1 (en) * | 2005-08-04 | 2007-02-15 | Sirtris Pharmaceuticals, Inc. | Imidazo [2,1-b] thiazole derivatives as sirtuin modulating compounds |
CA2645072A1 (en) * | 2006-03-08 | 2007-09-13 | Achillion Pharmaceuticals, Inc. | Substituted aminothiazole derivatives with anti-hcv activity |
JP5182088B2 (ja) | 2006-04-19 | 2013-04-10 | アステラス製薬株式会社 | アゾールカルボキサミド誘導体 |
CN101096363B (zh) * | 2006-06-27 | 2011-05-11 | 中国人民解放军军事医学科学院毒物药物研究所 | 2,4,5-三取代噻唑类化合物、其制备方法、药物组合物及其制药用途 |
WO2008016968A2 (en) | 2006-08-03 | 2008-02-07 | Trustees Of Tufts College | Non-flushing niacin analogues, and methods of use thereof |
MX2009002019A (es) | 2006-08-24 | 2009-03-09 | Novartis Ag | Derivados de 2-(pirazin-2-il)-tiazol y 2-(1h-pirazol-3-il)-tiazol asi como compuestos relacionados como inhibidores de la estearoil-coa-desaturasa (scd) para el tratamiento de trastornos metabolicos, cardiovasculares, y otros. |
EP2066664A1 (en) | 2006-09-22 | 2009-06-10 | Novartis AG | Heterocyclic organic compounds |
EP2097405A2 (en) * | 2006-11-21 | 2009-09-09 | Smithkline Beecham Corporation | Anti-viral compounds |
BRPI0720452A2 (pt) | 2006-12-20 | 2014-01-14 | Novartis Ag | Compostos orgânicos |
WO2008124300A1 (en) | 2007-04-10 | 2008-10-16 | National Health Research Institutes | Hepatitis c virus inhibitors |
EP2148878A4 (en) * | 2007-04-20 | 2011-08-10 | Merck Canada Inc | NEW HETEROAROMATIC COMPOUNDS AS INHIBITORS OF STEAROYL-COENZYME-A-DELTA-9-DESATURASE |
CN101801964A (zh) * | 2007-05-22 | 2010-08-11 | 艾其林医药公司 | 杂芳基取代的噻唑及其作为抗病毒剂的用途 |
US20100152208A1 (en) * | 2007-05-23 | 2010-06-17 | Merck Frosst Canada Ltd. | Bicyclic heteroaromatic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
WO2008154091A1 (en) | 2007-06-08 | 2008-12-18 | National Health Research Institutes | Thiourea derivatives |
CL2008001821A1 (es) | 2007-06-20 | 2009-03-13 | Sirtris Pharmaceuticals Inc | Compuestos derivados de imidazo[2,1-b]-tiazol; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de diabetes, sindrome metabolico, resistencia a la insulina, entre otras. |
CN101874029A (zh) * | 2007-07-13 | 2010-10-27 | 艾德克斯药品股份有限公司 | 作为代谢型谷氨酸受体调节剂的吡唑衍生物 |
GB2455111A (en) * | 2007-11-28 | 2009-06-03 | Addex Pharmaceuticals Sa | Metabotropic glutamate receptor (mGluR4) modulators having 5- or 6-membered N-heteroaryl ring substituted by both N-cyclylamino & 5-membered N-heteroaryl ring |
CN101801942B (zh) * | 2007-07-17 | 2013-03-27 | 美国艾森生物科学公司 | 杂环化合物和作为抗癌剂的用途 |
JP2010533658A (ja) * | 2007-07-20 | 2010-10-28 | メルク フロスト カナダ リミテツド | ステアロイル補酵素aデルタ−9デサチュラーゼ阻害剤としての二環性へテロ芳香族化合物 |
JP2010534722A (ja) * | 2007-07-27 | 2010-11-11 | ブリストル−マイヤーズ スクイブ カンパニー | 新規グルコキナーゼ活性化薬およびその使用方法 |
BRPI0815057B8 (pt) | 2007-08-03 | 2021-05-25 | Romark Laboratories Lc | composto, composição farmacêutica, e, uso de um composto |
EP2195312B1 (en) * | 2007-10-09 | 2012-11-21 | Merck Patent GmbH | Pyridine derivatives useful as glucokinase activators |
US8389736B2 (en) * | 2007-10-16 | 2013-03-05 | The Regents Of The University Of California | Compounds having activity in correcting mutant-CFTR processing and uses thereof |
CA2703106C (en) | 2007-10-24 | 2015-12-01 | Astellas Pharma Inc. | Azolecarboxamide derivatives as trka inhibitors |
EP2070925A1 (de) | 2007-12-10 | 2009-06-17 | Bayer Schering Pharma Aktiengesellschaft | Neue 2-substituierte Tiazol-4-carbonsäureamid-Derivative deren Herstellung und Verwendung als Arzneimittel |
EP2070924A1 (de) | 2007-12-10 | 2009-06-17 | Bayer Schering Pharma Aktiengesellschaft | Neue 2-Hetarylthiazol-4-carbonsäureamid-Derivative, deren Herstellung und Verwendung als Arzneimittel |
EP2070916A1 (de) | 2007-12-10 | 2009-06-17 | Bayer Schering Pharma Aktiengesellschaft | 2-Aryl-thiazol-4-carbonsäureamid-Derivate, deren Herstellung und Verwendung als Arzneimittel |
TWI361808B (en) | 2008-01-08 | 2012-04-11 | Nat Health Research Institutes | Imidazolidinone and imidazolidinethione derivatives |
EP2101173A1 (en) | 2008-03-14 | 2009-09-16 | Vivalis | In vitro method to determine whether a drug candidate active against a target protein is active against a variant of said protein |
US8198284B2 (en) | 2008-04-30 | 2012-06-12 | National Health Research Institutes | Treatment of neurodegenerative disorders with thiourea compounds |
US8106209B2 (en) * | 2008-06-06 | 2012-01-31 | Achillion Pharmaceuticals, Inc. | Substituted aminothiazole prodrugs of compounds with anti-HCV activity |
US8362050B2 (en) | 2008-06-24 | 2013-01-29 | Irm Llc | Compounds and methods for modulating G protein-coupled receptors |
EP2306836B1 (en) * | 2008-07-01 | 2016-09-07 | PTC Therapeutics, Inc. | Bmi-1 protein expression modulators |
AU2009271019A1 (en) | 2008-07-14 | 2010-01-21 | Gilead Sciences, Inc. | Fused heterocyclyc inhibitors of histone deacetylase and/or cyclin-dependent kinases |
WO2010009139A2 (en) | 2008-07-14 | 2010-01-21 | Gilead Colorado, Inc. | Imidazolyl pyrimidine inhibitor compounds |
US8344018B2 (en) | 2008-07-14 | 2013-01-01 | Gilead Sciences, Inc. | Oxindolyl inhibitor compounds |
MX2011001090A (es) | 2008-07-28 | 2011-03-15 | Gilead Sciences Inc | Compuestos de inhibidor de desacetilasa de histona de cicloalquilideno y heterocicloalquilideno. |
MX2011001662A (es) | 2008-08-11 | 2011-03-24 | Glaxosmithkline Llc | Derivados de purina para usarse en el tratamiento de enfermedades alergicas, inflamatorias e infecciosas. |
UA103195C2 (uk) | 2008-08-11 | 2013-09-25 | Глаксосмитклайн Ллк | Похідні пурину для застосування у лікуванні алергій, запальних та інфекційних захворювань |
CN102176911B (zh) | 2008-08-11 | 2014-12-10 | 葛兰素史密丝克莱恩有限责任公司 | 新的腺嘌呤衍生物 |
US9540322B2 (en) | 2008-08-18 | 2017-01-10 | Yale University | MIF modulators |
CN102186833A (zh) * | 2008-08-18 | 2011-09-14 | 耶鲁大学 | Mif调节剂 |
US9643922B2 (en) | 2008-08-18 | 2017-05-09 | Yale University | MIF modulators |
GB0900388D0 (en) | 2009-01-12 | 2009-02-11 | Addex Pharmaceuticals Sa | New compounds |
AP3074A (en) | 2009-05-12 | 2014-12-31 | Romark Lab Lc | Haloalkyl heteroaryl benzamide compounds |
EP2440519A1 (en) | 2009-06-08 | 2012-04-18 | Gilead Sciences, Inc. | Alkanoylamino benzamide aniline hdac inihibitor compounds |
MX2011013166A (es) | 2009-06-08 | 2012-01-30 | Gilead Sciences Inc | Compuestos inhibidores de hdac de cicloalquilcarbamatobenzamida-an ilina. |
CN101928283A (zh) * | 2009-06-25 | 2010-12-29 | 上海唐润医药科技有限公司 | 具有抗hcv活性的化合物及其用途 |
JP5932640B2 (ja) | 2009-06-26 | 2016-06-08 | ロマーク ラボラトリーズ エル.シー. | インフルエンザを治療するための化合物および方法 |
EP2534148A1 (en) | 2010-02-10 | 2012-12-19 | GlaxoSmithKline LLC | Purine derivatives and their pharmaceutical uses |
AU2011214468B2 (en) | 2010-02-10 | 2015-05-28 | Glaxosmithkline Llc | 6-amino-2-{ [ (1S)-1-methylbutyl] oxy}-9-[5-(1-piperidinyl)-7,9-dihydro-8H-purin-8-one maleate |
JP2013520439A (ja) * | 2010-02-19 | 2013-06-06 | アセア バイオサイエンシズ インコーポレイテッド | 抗癌剤としての複素環式化合物および使用 |
WO2011115998A2 (en) * | 2010-03-17 | 2011-09-22 | Taivex Therapeutics Inc. | Modulators of hec1 activity and methods therefor |
WO2012037351A1 (en) * | 2010-09-17 | 2012-03-22 | Glaxosmithkline Llc | Compounds |
WO2012037349A2 (en) * | 2010-09-17 | 2012-03-22 | Glaxosmithkline Llc | Compounds |
WO2012075393A2 (en) * | 2010-12-02 | 2012-06-07 | President And Fellows Of Harvard College | Activators of proteasomal degradation and uses thereof |
US8835456B1 (en) | 2011-03-18 | 2014-09-16 | Achillion Pharmaceuticals, Inc. | NS5A inhibitors useful for treating HCV |
CN103097367B (zh) * | 2011-04-02 | 2014-12-03 | 中国人民解放军军事医学科学院毒物药物研究所 | 苯丙酸化合物、其制备方法及其医药用途 |
AP2013007263A0 (en) | 2011-05-27 | 2013-11-30 | Achillion Pharmaceuticals Inc | Substituted aliphanes, cyclophanes, heteraphanes, heterophanes, hetero-heteraphanes and metallocenesuseful for treating HCV infections |
WO2013033037A2 (en) * | 2011-08-26 | 2013-03-07 | The Regents Of The University Of California | Novel antiprion compounds |
WO2013049407A2 (en) * | 2011-09-30 | 2013-04-04 | Kineta, Inc | Anti-viral compounds |
WO2013052613A1 (en) * | 2011-10-04 | 2013-04-11 | Institute For Hepatitis And Virus Research | Substituted aminothiazoles as inhibitors of cancers, including hepatocellular carcinoma, and as inhibitors of hepatitis virus replication |
US9926309B2 (en) | 2011-10-05 | 2018-03-27 | The Board Of Trustees Of The Leland Stanford Junior University | Pi-kinase inhibitors with anti-infective activity |
CN104080452A (zh) | 2011-10-26 | 2014-10-01 | 美国政府健康及人类服务部 | 用小分子chk2抑制剂治疗hcv感染的方法 |
US11071736B2 (en) | 2011-11-21 | 2021-07-27 | Taivex Therapeutics Corporation | Modulators of HEC1 activity and methods therefor |
EP2869897A4 (en) | 2012-07-06 | 2016-09-28 | Univ Duke | ACTIVATION OF THE TRPV4 ION CHANNEL BY PHYSICAL STIMULI AND IMPORTANT ROLE FOR TRPV4 IN ORGANIC INFLAMMATION AND JUCKREIZ |
MX2015001793A (es) * | 2012-08-09 | 2015-05-07 | Neuropore Therapies Inc | Derivados de benceno sustituidos con arilo y heteroarilo como moduladores de las trayectorias de señalizacion de cinasa pi3. |
WO2014063167A1 (en) * | 2012-10-19 | 2014-04-24 | The Broad Institute, Inc. | Thiazole-based inhibitors of scavenger receptor bi |
WO2014063168A1 (en) | 2012-10-19 | 2014-04-24 | The Broad Institute, Inc. | Heterocycle-bisamide inhibitors of scavenger receptor bl |
US9382218B2 (en) * | 2013-03-05 | 2016-07-05 | Hoffmann-La Roche Inc. | N-heteroaryl substituted aniline derivatives as HCV-antivirals |
TW201534586A (zh) | 2013-06-11 | 2015-09-16 | Orion Corp | 新穎cyp17抑制劑/抗雄激素劑 |
WO2015002926A1 (en) | 2013-07-02 | 2015-01-08 | Bristol-Myers Squibb Company | Tricyclic pyrido-carboxamide derivatives as rock inhibitors |
TW201506024A (zh) | 2013-07-02 | 2015-02-16 | 必治妥美雅史谷比公司 | 作為有效rock抑制劑的三環甲醯胺衍生物 |
US9353078B2 (en) * | 2013-10-01 | 2016-05-31 | New York University | Amino, amido and heterocyclic compounds as modulators of rage activity and uses thereof |
CA2938476A1 (en) | 2014-02-20 | 2015-08-27 | Glaxosmithkline Intellectual Property (No.2) Limited | Pyrrolo[3,2-d]pyrimidine derivatives as inducers of human interferon |
US10329265B2 (en) | 2014-08-22 | 2019-06-25 | Duke University | TRPA1 and TRPV4 inhibitors and methods of using the same for organ-specific inflammation and itch |
TW201629035A (zh) * | 2014-10-06 | 2016-08-16 | 奇尼塔公司 | 抗病毒化合物、醫藥組合物及其使用方法 |
MX2017006302A (es) | 2014-11-13 | 2018-02-16 | Glaxosmithkline Biologicals Sa | Derivados de adenina que son utiles en el tratamiento de enfermedades alergicas u otras afecciones inflamatorias. |
US11229628B2 (en) | 2015-01-09 | 2022-01-25 | Duke University | TRPA1 and TRPV4 inhibitors and methods of using the same for organ-specific inflammation and itch |
EP3053920B1 (en) * | 2015-02-05 | 2020-04-08 | AB Science | Compounds with anti-tumoral activity |
EP3262040A4 (en) * | 2015-02-27 | 2018-09-12 | The Regents of The University of California | Small molecules that enable cartilage rejuvanation |
RU2722019C2 (ru) | 2015-12-03 | 2020-05-26 | Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед | Циклические пуриновые динуклеотиды в качестве модуляторов sting |
CN105524056A (zh) * | 2016-01-05 | 2016-04-27 | 中山大学肿瘤防治中心 | 一种氨基噻唑化合物及其制备方法和应用 |
WO2017147526A1 (en) | 2016-02-26 | 2017-08-31 | The Board Of Trustees Of The Leland Stanford Junior University | Pi-kinase inhibitors with anti-infective activity |
WO2017177200A1 (en) | 2016-04-07 | 2017-10-12 | Duke University | Small molecule dual-inhibitors of trpv4 and trpa1 for sanitizing and anesthetizing |
RU2018137389A (ru) | 2016-04-07 | 2020-05-12 | Глаксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед | Гетероциклические амиды, полезные в качестве модуляторов |
IL295649A (en) | 2016-04-07 | 2022-10-01 | Glaxosmithkline Ip Dev Ltd | Heterocyclic amides are useful as protein modulators |
CN109562113A (zh) | 2016-05-10 | 2019-04-02 | C4医药公司 | 用于靶蛋白降解的螺环降解决定子体 |
WO2017197055A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Heterocyclic degronimers for target protein degradation |
EP3455218A4 (en) | 2016-05-10 | 2019-12-18 | C4 Therapeutics, Inc. | C3 CARBON-BASED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION |
WO2018039615A1 (en) * | 2016-08-26 | 2018-03-01 | The Regents Of The University Of California | Hair follicle stem cell activation and hair growth |
US10875861B1 (en) | 2017-05-26 | 2020-12-29 | Rutgers, The State University Of New Jersey | Therapeutic compounds |
CA3077337A1 (en) | 2017-10-05 | 2019-04-11 | Glaxosmithkline Intellectual Property Development Limited | Modulators of stimulator of interferon genes (sting) |
TW201927771A (zh) | 2017-10-05 | 2019-07-16 | 英商葛蘭素史密斯克藍智慧財產發展有限公司 | 可作為蛋白質調節劑之雜環醯胺及其使用方法 |
KR102639231B1 (ko) | 2017-10-30 | 2024-02-22 | 뉴로포레 테라피스, 인코포레이티드 | 치환된 페닐 설폰일 페닐 트리아졸 싸이온 및 이의 용도 |
WO2019164996A1 (en) | 2018-02-21 | 2019-08-29 | Southern Research Institute | 2-aminoaryl-5-aryloxazole analogs for the treatment of neurodegenerative diseases |
US20210100795A1 (en) | 2018-04-03 | 2021-04-08 | Blueprint Medicines Corporation | Ret inhibitor for use in treating cancer having a ret alteration |
GB201807924D0 (en) | 2018-05-16 | 2018-06-27 | Ctxt Pty Ltd | Compounds |
US11718593B2 (en) | 2018-05-17 | 2023-08-08 | Southern Research Institute | 2,5-aryl-thiazole analogs for the treatment of neurodegenerative diseases |
CN114391015A (zh) | 2019-05-16 | 2022-04-22 | 斯汀塞拉股份有限公司 | 苯并[b][1,8]萘啶乙酸衍生物和使用方法 |
CN114302875A (zh) | 2019-05-16 | 2022-04-08 | 斯汀塞拉股份有限公司 | 氧代吖啶基乙酸衍生物及使用方法 |
GB201910305D0 (en) | 2019-07-18 | 2019-09-04 | Ctxt Pty Ltd | Compounds |
GB201910304D0 (en) | 2019-07-18 | 2019-09-04 | Ctxt Pty Ltd | Compounds |
US20230167103A1 (en) | 2020-04-24 | 2023-06-01 | Bayer Aktiengesellschaft | Substituted aminothiazoles as dgkzeta inhibitors for immune activation |
AU2022334296A1 (en) * | 2021-08-25 | 2024-03-07 | PIC Therapeutics, Inc. | Eif4e inhibitors and uses thereof |
CN114249702B (zh) * | 2022-01-12 | 2023-09-05 | 沈阳药科大学 | N-芳基-[2,4′-双噻唑]-2′-胺类化合物及其制备与用途 |
WO2023135330A1 (en) * | 2022-01-17 | 2023-07-20 | Centre National De La Recherche Scientifique | Deoxycytidine kinase inhibitors |
Family Cites Families (77)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2474194A (en) * | 1941-08-30 | 1949-06-21 | American Cyanamid Co | N-heterocyclic substituted guanamines |
US3458526A (en) * | 1966-09-26 | 1969-07-29 | Upjohn Co | Certain 2-amino-4,5-bis(p-methoxyphenyl)thiazoles |
US3467666A (en) * | 1966-11-07 | 1969-09-16 | Geigy Chem Corp | 2-substituted aminothiazoles |
BE795907A (fr) * | 1972-02-25 | 1973-06-18 | Luso Farmaco Inst | 2-amino-4-arylthiazoles 5-substitues et leur preparation |
CA1051906A (en) * | 1973-10-24 | 1979-04-03 | Shionogi And Co. | Thiazole derivatives and production thereof |
DK150068C (da) | 1978-06-02 | 1987-06-29 | Pfizer | Analogifremgangsmaade til fremstilling af aminothiazoler |
JPS6339868A (ja) * | 1986-08-04 | 1988-02-20 | Otsuka Pharmaceut Factory Inc | ジ低級アルキルフエノ−ル誘導体 |
DD271258A1 (de) * | 1988-04-06 | 1989-08-30 | Univ Leipzig | Mittel zur chemotherapie von kulturpflanzenvirosen |
DE4029771A1 (de) * | 1990-09-20 | 1992-03-26 | Basf Ag | N-heteroaryl-2-nitroaniline |
DE69526958T2 (de) * | 1994-11-29 | 2003-01-16 | Hisamitsu Pharmaceutical Co | Antibakterielle oder bakterizide mittel, die 2-aminothiazolderivate und deren salze enthalten |
DK0871619T3 (da) * | 1995-12-29 | 2003-03-03 | Boehringer Ingelheim Pharma | Phenylthiazolderivater med antiherpesvirusegenskaber |
MY128323A (en) * | 1996-09-30 | 2007-01-31 | Otsuka Pharma Co Ltd | Thiazole derivatives for inhibition of cytokine production and of cell adhesion |
WO2000006575A2 (en) | 1998-07-28 | 2000-02-10 | Smithkline Beecham Plc | Azabicyclic compounds |
EP1114039A1 (en) * | 1998-09-18 | 2001-07-11 | Vertex Pharmaceuticals Incorporated | INHIBITORS OF p38 |
WO2000033837A2 (en) | 1998-12-07 | 2000-06-15 | Smithkline Beecham Corporation | Myt1 kinase inhibitors |
WO2001021160A2 (en) | 1999-09-23 | 2001-03-29 | Axxima Pharmaceuticals Aktiengesellschaft | Carboxymide and aniline derivatives as selective inhibitors of pathogens |
TWI284639B (en) | 2000-01-24 | 2007-08-01 | Shionogi & Co | A compound having thrombopoietin receptor agonistic effect |
WO2001064674A1 (en) | 2000-03-01 | 2001-09-07 | Janssen Pharmaceutica N.V. | 2,4-disubstituted thiazolyl derivatives |
US6586453B2 (en) * | 2000-04-03 | 2003-07-01 | 3-Dimensional Pharmaceuticals, Inc. | Substituted thiazoles and the use thereof as inhibitors of plasminogen activator inhibitor-1 |
WO2002030357A2 (en) * | 2000-10-11 | 2002-04-18 | Chemocentryx, Inc. | Compounds and methods for modulating ccr4 function |
GB0028383D0 (en) * | 2000-11-21 | 2001-01-03 | Novartis Ag | Organic compounds |
WO2002051410A2 (en) | 2000-12-22 | 2002-07-04 | Akzo Nobel N.V. | Phenylthiazole and thiazoline derivatives and their use as antiparasitics |
CA2436739A1 (en) | 2000-12-26 | 2002-07-04 | Takeda Chemical Industries, Ltd. | Combination agent |
US7169931B2 (en) * | 2001-01-26 | 2007-01-30 | Shionogi & Co., Ltd. | Cyclic compounds exhibiting thrombopoietin receptor agonism |
WO2002094264A1 (en) * | 2001-05-23 | 2002-11-28 | Tularik Inc. | Ccr4 antagonists |
HN2002000156A (es) | 2001-07-06 | 2003-11-27 | Inc Agouron Pharmaceuticals | Derivados de benzamida tiazol y composiciones farmaceuticas para inhibir la proliferacion de celulas y metodos para su utilización. |
HUP0401748A3 (en) | 2001-08-13 | 2011-03-28 | Janssen Pharmaceutica Nv | 2-amino-4,5-trisubstituted thiazolyl derivatives, process for their preparation and pharmaceutical compositions containing them |
US20040198773A1 (en) | 2001-09-26 | 2004-10-07 | Barry Hart | Substituted 3-pyridyl oxazoles as c17,20 lyase inhibitors |
US20040267017A1 (en) | 2001-09-26 | 2004-12-30 | Bierer Donald E | 3-pyridyl or 4-isoquinolinyl thiazoles as c17, 20 lyase inhibitors |
US20040236110A1 (en) | 2001-09-26 | 2004-11-25 | Ladouceur Gaetan H | Substituted 3-pyridyl indoles and indazoles as c17,20 lyase inhibitors |
WO2003027095A1 (en) | 2001-09-26 | 2003-04-03 | Bayer Pharmaceuticals Corporation | Substituted 3-pyridyl tetrazoles as steroid c17,20 lyase inhibitors |
US20040209924A1 (en) | 2001-09-26 | 2004-10-21 | Barry Hart | Substituted 3-pyridyl imidazoles as c17,20 lyase inhibitors |
MXPA04003170A (es) | 2001-10-03 | 2004-07-08 | Pharmacia Corp | Compuestos policiclicos, sustituidos, provisto de 5 miembros, utiles para la inhibicion selectiva de la cascada de coagulacion. |
WO2003028729A2 (en) | 2001-10-03 | 2003-04-10 | Pharmacia Corporation | Prodrugs of substituted polycyclic compounds useful for selective inhibition of the coagulation cascade |
US6881746B2 (en) | 2001-12-03 | 2005-04-19 | Novo Nordick A/S | Glucagon antagonists/inverse agonists |
WO2003048140A1 (fr) | 2001-12-03 | 2003-06-12 | Japan Tobacco Inc. | Compose azole et utilisation medicinale de celui-ci |
US6936629B2 (en) | 2001-12-21 | 2005-08-30 | Virochem Pharma Inc. | Compounds and methods for the treatment or prevention of flavivirus infections |
CA2474322A1 (en) | 2002-01-25 | 2003-07-31 | Kylix Pharmaceuticals B.V. | 4(hetero-) aryl substituted (thia-/oxa-/pyra) zoles for inhibition of tie-2 |
US20030158199A1 (en) | 2002-01-25 | 2003-08-21 | Kylix, B.V. | Novel compounds for inhibition of Tie-2 |
KR100895632B1 (ko) | 2002-02-06 | 2009-05-07 | 쟈판에나지 덴시자이료 가부시키가이샤 | 수소화 정제 촉매의 제조 방법 |
BRPI0313165B8 (pt) | 2002-08-02 | 2021-05-25 | Ab Science | 2-(3-aminoaril)amino-4-aril-tiazóis e sua utilização como inibidores de c-kit |
RU2324685C2 (ru) * | 2002-08-07 | 2008-05-20 | Ф.Хоффманн-Ля Рош Аг | Производные тиазола, способ их получения и применение, фармацевтическая композиция, обладающая свойствами антагонистов рецепторов npy |
KR20110010824A (ko) | 2003-01-14 | 2011-02-07 | 아레나 파마슈티칼스, 인크. | 대사 조절제로서의 1,2,3-삼치환된 아릴 및 헤테로아릴 유도체, 및 당뇨병 및 고혈당증을 비롯한 이에 관련된 장애의 예방 및 치료 |
EP2562158A1 (en) * | 2003-02-10 | 2013-02-27 | Vertex Pharmaceuticals Incorporated | Processes for the preparation of n-heteroaryl-N-aryl-amines by reacting an N-aryl carbamic acid ester with a halo-heteroaryl and analogous processes |
US7265138B2 (en) | 2003-02-10 | 2007-09-04 | Amgen Inc. | Vanilloid receptor ligands and their use in treatments |
WO2004072070A1 (en) | 2003-02-12 | 2004-08-26 | Pfizer Inc. | Antiproliferative 2-(sulfo-phenyl)-aminothiazole derivatives |
CN1747936A (zh) | 2003-02-12 | 2006-03-15 | 特兰斯泰克制药公司 | 作为治疗试剂的取代吡咯衍生物 |
ATE393243T1 (de) | 2003-02-27 | 2008-05-15 | Ab Science | Diagnostisches verfahren der mastozytose |
TW200505902A (en) | 2003-03-20 | 2005-02-16 | Schering Corp | Cannabinoid receptor ligands |
WO2004092145A1 (en) | 2003-04-15 | 2004-10-28 | Pfizer Inc. | Alpha substituted carboxylic acid as ppar modulators |
FR2854158B1 (fr) * | 2003-04-25 | 2006-11-17 | Sanofi Synthelabo | Derives de 2-acylamino-4-phenylethiazole, leur preparation et leur application en therapeutique |
US20070191267A1 (en) | 2003-04-28 | 2007-08-16 | Ab Science | Use of tyrosine kinase inhibitors for treating cerebral ischemia |
WO2004098612A2 (en) | 2003-05-07 | 2004-11-18 | Ab Science | Calcitriol analogs of uses thereof |
CN102584813B (zh) | 2003-05-14 | 2016-07-06 | Ngc药物公司 | 化合物及其在调节淀粉样蛋白β中的用途 |
PT1635824E (pt) | 2003-06-03 | 2009-11-24 | Novartis Ag | Inibidores de p-38 à base de heterociclos de 5 membros |
WO2005000309A2 (en) | 2003-06-27 | 2005-01-06 | Ionix Pharmaceuticals Limited | Chemical compounds |
AR045047A1 (es) | 2003-07-11 | 2005-10-12 | Arena Pharm Inc | Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos |
ATE395052T1 (de) | 2003-08-15 | 2008-05-15 | Ab Science | Verwendung von c-kit-inhibitoren für die behandlung von typ-2-diabetes |
DE602004010291T2 (de) | 2003-09-30 | 2008-10-09 | Tibotec Pharmaceuticals Ltd. | Hcv-hemmende sulfonamide |
US20070269420A1 (en) * | 2003-11-24 | 2007-11-22 | Chunduru Srinivas K | Compounds, Compositions and Methods for Treatment and Prophylaxis of Hepatitis C Viral Infections and Associated Diseases |
CN1934107A (zh) | 2004-01-30 | 2007-03-21 | Ab科学公司 | 作为酪氨酸激酶抑制剂的2-(3-取代芳基)氨基-4-芳基-噻唑 |
WO2005077368A2 (en) | 2004-02-03 | 2005-08-25 | Astrazeneca Ab | Treatment of gastro-esophageal reflux disease (gerd) |
TW200538433A (en) | 2004-02-24 | 2005-12-01 | Irm Llc | Immunosuppressant compounds and compositiions |
US20050227989A1 (en) | 2004-04-13 | 2005-10-13 | Icagen, Inc. | Polycyclic thiazoles as potassium ion channel modulators |
CA2564568A1 (en) | 2004-04-20 | 2005-11-03 | Ab Science | Use of c-kit inhibitors for treating inflammatory muscle disorders including myositis and muscular dystrophy |
WO2005102318A1 (en) | 2004-04-20 | 2005-11-03 | Ab Science | Use of c-kit inhibitors for treating hiv related diseases |
CA2564570A1 (en) | 2004-04-23 | 2005-11-03 | Ab Science | Use of c-kit inhibitors for treating plasmodium related diseases |
WO2005102326A2 (en) | 2004-04-23 | 2005-11-03 | Ab Science | Use of c-kit inhibitors for treating renal diseases |
CA2564574A1 (en) | 2004-04-23 | 2005-11-03 | Ab Science | Use of c-kit inhibitors for treating fibrosis |
CA2566104A1 (en) | 2004-05-18 | 2005-12-01 | Ab Science | Use of mast cells inhibitors for treating patients exposed to chemical or biological weapons |
WO2005115385A1 (en) | 2004-05-24 | 2005-12-08 | Ab Science | Use of c-kit inhibitors for treating acne |
WO2005115304A2 (en) | 2004-05-24 | 2005-12-08 | Ab Science | Use of c-kit inhibitors for treating fibrodysplasia |
MX2007003377A (es) | 2004-09-23 | 2007-05-10 | Pfizer Prod Inc | Agonistas del receptor de trombopoyetina. |
CN101248052A (zh) | 2005-05-11 | 2008-08-20 | 艾博特公司 | 香草素受体亚型1(vr1)拮抗剂及其用途 |
US8735595B2 (en) | 2006-02-15 | 2014-05-27 | Abbvie Inc. | Acetyl-CoA carboxylase (ACC) inhibitors and their use in diabetes, obesity and metabolic syndrome |
CA2645072A1 (en) * | 2006-03-08 | 2007-09-13 | Achillion Pharmaceuticals, Inc. | Substituted aminothiazole derivatives with anti-hcv activity |
CN101801964A (zh) * | 2007-05-22 | 2010-08-11 | 艾其林医药公司 | 杂芳基取代的噻唑及其作为抗病毒剂的用途 |
-
2006
- 2006-05-09 AU AU2006244203A patent/AU2006244203B2/en not_active Ceased
- 2006-05-09 CA CA002607617A patent/CA2607617A1/en not_active Abandoned
- 2006-05-09 CN CNA200680025066XA patent/CN101247807A/zh active Pending
- 2006-05-09 BR BRPI0608910-0A patent/BRPI0608910A2/pt not_active IP Right Cessation
- 2006-05-09 NZ NZ563866A patent/NZ563866A/en not_active IP Right Cessation
- 2006-05-09 AP AP2007004268A patent/AP2358A/xx active
- 2006-05-09 MX MX2007013955A patent/MX2007013955A/es not_active Application Discontinuation
- 2006-05-09 KR KR1020077028496A patent/KR20080019213A/ko not_active Application Discontinuation
- 2006-05-09 UA UAA200713741A patent/UA92746C2/ru unknown
- 2006-05-09 EA EA200702445A patent/EA200702445A1/ru unknown
- 2006-05-09 JP JP2008511226A patent/JP2008540537A/ja active Pending
- 2006-05-09 WO PCT/US2006/017692 patent/WO2006122011A2/en active Application Filing
- 2006-05-09 US US11/431,155 patent/US8088806B2/en not_active Expired - Fee Related
- 2006-05-09 SG SG201001098-1A patent/SG159561A1/en unknown
- 2006-05-09 EP EP06770077A patent/EP1879575A2/en not_active Withdrawn
-
2007
- 2007-10-28 IL IL186970A patent/IL186970A0/en unknown
- 2007-11-09 NO NO20075723A patent/NO20075723L/no not_active Application Discontinuation
- 2007-11-13 ZA ZA200709751A patent/ZA200709751B/xx unknown
-
2011
- 2011-11-30 US US13/307,761 patent/US20120108576A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
AP2358A (en) | 2012-01-30 |
WO2006122011A2 (en) | 2006-11-16 |
US8088806B2 (en) | 2012-01-03 |
MX2007013955A (es) | 2008-02-05 |
IL186970A0 (en) | 2008-02-09 |
UA92746C2 (en) | 2010-12-10 |
JP2008540537A (ja) | 2008-11-20 |
AU2006244203A1 (en) | 2006-11-16 |
BRPI0608910A2 (pt) | 2010-02-17 |
US20120108576A1 (en) | 2012-05-03 |
AP2007004268A0 (en) | 2007-12-31 |
CA2607617A1 (en) | 2006-11-16 |
EA200702445A1 (ru) | 2008-04-28 |
SG159561A1 (en) | 2010-03-30 |
US20070004711A1 (en) | 2007-01-04 |
CN101247807A (zh) | 2008-08-20 |
AU2006244203B2 (en) | 2012-05-03 |
KR20080019213A (ko) | 2008-03-03 |
WO2006122011A3 (en) | 2007-05-03 |
NO20075723L (no) | 2008-02-05 |
NZ563866A (en) | 2011-03-31 |
EP1879575A2 (en) | 2008-01-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA200709751B (en) | Thiazole compounds and methods of use | |
IL196956A0 (en) | Aza-benzofuranyl compounds and methods of use | |
EP2023718A4 (en) | CREATINLIGATE COMPOUNDS AND APPLICATION METHOD THEREFOR | |
IL176958A0 (en) | Compounds and methods of use | |
IL182203A0 (en) | Thiadiazole compounds and methods of use | |
IL185309A0 (en) | Isoqunoline compounds and methods of use thereof | |
IL189771A0 (en) | Raf inhibitor compounds and methods of use thereof | |
ZA200710969B (en) | Raf inhibitor compounds and methods of use thereof | |
IL197060A0 (en) | Aza-benzothiophenyl compounds and methods of use | |
ZA200802501B (en) | Indenoisoquinolinone analogs and methods of use thereof | |
ZA200808017B (en) | Tetrahydropyridothienopyrimidine compounds and methods of use thereof | |
HK1118829A1 (en) | Thiazole derivatives and use thereof | |
HK1135099A1 (en) | Aza-indolyl compounds and methods of use | |
ZA200710104B (en) | Thiazole derivatives and use thereof | |
IL190226A0 (en) | Organometallic compounds and methods of use thereof | |
EP1812451A4 (en) | COMPOUNDS AND METHODS OF USE THEREOF | |
HK1161122A1 (en) | Use of 24-norudca 24-norudca | |
EP1946007A4 (en) | ANDROSTERONE DERIVATIVES AND METHODS OF USE | |
GB0520930D0 (en) | Composition and method of use | |
ZA200900896B (en) | Aza-benzofuranyl compounds and methods of use | |
EP1931370A4 (en) | USE OF DES-ASPARTATE-ANGIOTENSIN I | |
EP1978999A4 (en) | ISOLATED MCPIP PROTEIN AND METHODS OF USE | |
ZA200901009B (en) | Aza-benzothiophenyl compounds and methods of use | |
ZA200710971B (en) | Elasmobranch-repelling compounds and methods of use | |
GB0507211D0 (en) | Method and uses of compounds |